Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Assunto principal
Intervalo de ano de publicação
1.
J Bras Nefrol ; 46(1): 18-28, 2024.
Artigo em Inglês, Português | MEDLINE | ID: mdl-37527531

RESUMO

INTRODUCTION: Nephrotic syndrome (NS) is one of the reasons of end-stage kidney disease, and elucidating the pathogenesis and offer new treatment options is important. Oxidative stress might trigger pathogenesis systemically or isolated in the kidneys. Octreotide (OCT) has beneficial antioxidant effects. We aimed to investigate the source of oxidative stress and the effect of OCT on experimental NS model. METHODS: Twenty-four non-uremic Wistar albino rats were divided into 3 groups. Control group, 2 mL saline intramuscular (im); NS group, adriamycin 5 mg/kg intravenous (iv); NS treatment group, adriamycin 5 mg/kg (iv) and OCT 200 mcg/kg (im) were administered at baseline (Day 0). At the end of 21 days, creatinine and protein levels were measured in 24-hour urine samples. Erythrocyte and renal catalase (CAT) and thiobarbituric acid reactive substance (TBARS) were measured. Renal histology was also evaluated. RESULTS: There was no significant difference among the 3 groups in terms of CAT and TBARS in erythrocytes. Renal CAT level was lowest in NS group, and significantly lower than the control group. In treatment group, CAT level significantly increased compared with NS group. In terms of renal histology, tubular and interstitial evaluations were similar in all groups. Glomerular score was significantly higher in NS group compared with control group and it was significantly decreased in treatment group compared to NS group. CONCLUSIONS: Oxidative stress in NS might be due to the decrease in antioxidant protection mechanism in kidney. Octreotide improves antioxidant levels and histology in renal tissue and might be a treatment option.


Assuntos
Síndrome Nefrótica , Ratos , Animais , Síndrome Nefrótica/induzido quimicamente , Síndrome Nefrótica/tratamento farmacológico , Doxorrubicina/efeitos adversos , Doxorrubicina/metabolismo , Antioxidantes/farmacologia , Antioxidantes/uso terapêutico , Octreotida/efeitos adversos , Substâncias Reativas com Ácido Tiobarbitúrico/efeitos adversos , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo , Rim/patologia , Estresse Oxidativo , Ratos Wistar , Eritrócitos/metabolismo , Eritrócitos/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA